「68Ga」Ga-FAPI-46 PET/CT与「18F」FDG PET/CT在胃食管腺癌初始分期中的临床价值前瞻性试验
该前瞻性北欧试验纳入20例可手术切除并接受围手术期化疗的胃腺癌或胃食管交界腺癌患者,比较「68Ga」Ga-FAPI-46 PET/CT与「18F」FDG PET/CT及增强CT在初始分期和管理中的影响。结果显示FAPI-46 PET主要价值在于检出FDG PET和ceCT阴性的远处转移,使4例(20%)临床转移分期上调、3例(15%)治疗意图由根治转为姑息;在原发瘤和区域淋巴结评估方面无明显优势。
要点
- FAPI-46 PET检出FDG PET和ceCT阴性的远处转移,4例(20%)转移分期上调。
- 3例(15%)因FAPI-46 PET结果治疗意图由根治改为姑息。
- 原发瘤检测率FAPI-46与FDG PET均为90%(95%CI 68%-99%),18例(90%)一致。
核心结论
- 「68Ga」Ga-FAPI-46 PET的主要临床价值是检出「18F」FDG PET和ceCT阴性的远处转移,可能影响患者管理。
- 「68Ga」Ga-FAPI-46 PET在原发瘤和区域淋巴结评估方面无明显优势。
研究设计与样本
- 前瞻性临床试验,2024年2月8日至2025年9月26日连续纳入20例适合手术切除并围手术期化疗的胃腺癌或胃食管交界腺癌患者。
- 15例(75%)为胃食管交界腺癌,5例(25%)为胃癌,均为腺癌。
- 「68Ga」Ga-FAPI-46 PET/CT图像去标识化后在试验结束后呈现给治疗临床医生,据此确定分期和暂定患者管理。
主要发现
- 原发瘤方面,「68Ga」Ga-FAPI-46与「18F」FDG PET/CT在18例(90%)中一致,两种模态检测率均为90%(95%CI 68%-99%)。
- 临床淋巴结分期方面,ceCT检出淋巴结数多于「68Ga」Ga-FAPI-46 PET和「18F」FDG PET单独检出(分别为81、53、44枚)。
- 「68Ga」Ga-FAPI-46 PET未检出ceCT之外额外的淋巴结。
- 「18F」FDG PET在5例患者中额外检出6枚淋巴结,使4例(20%)较「68Ga」Ga-FAPI-46 PET和ceCT出现临床淋巴结分期上调。
- 「68Ga」Ga-FAPI-46 PET因检出潜在远处转移(1例腹膜转移和3例肝转移)使4例(20%)临床转移分期上调,其中3例(15%)治疗建议由根治意图转为姑息治疗。
临床怎么用
- 「68Ga」Ga-FAPI-46 PET可用于检出「18F」FDG PET和ceCT阴性的远处转移,辅助转移分期并可能改变治疗意图。
- 在原发瘤和区域淋巴结评估方面,「68Ga」Ga-FAPI-46 PET未见优于「18F」FDG PET或ceCT的表现。
局限性
- 研究人群相对较小(20例),且以胃食管交界腺癌为主(15例,75%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previous studies have demonstrated promising results for radiolabeled fibroblast activation protein inhibitor (FAPI) PET/CT in gastric cancer (GC) when compared with [18F]FDG PET/CT. In this prospective clinical trial, we assessed the impact of [68Ga]Ga-FAPI-46 PET/CT compared with [18F]FDG PET/CT and contrast-enhanced CT (ceCT) on primary staging and management of Danish patients with GC and gastroesophageal junction cancer (GEJC). Methods: Between February 8, 2024, and September 26, 2025, consecutive patients with GC or GEJC who were candidates for surgical resection and perioperative chemotherapy were included in this trial. [68Ga]Ga-FAPI-46 PET/CT images were deidentified and presented to the treating clinicians after the trial, at which point [68Ga]Ga-FAPI-46 PET/CT-based staging and tentative patient management were determined. Results: Twenty patients were included in the trial, including 15 (75%) with GEJC and 5 (25%) with GC; all patients were diagnosed with adenocarcinoma. For the primary tumor, [68Ga]Ga-FAPI-46 and [18F]FDG PET/CT agreed in 18 (90%) of cases, and both modalities demonstrated a detection rate of 90% (95% CI, 68%-99%). For clinical nodal staging, ceCT detected more lymph nodes than did [68Ga]Ga-FAPI-46 PET and [18F]FDG PET alone (81 vs. 53 vs. 44, respectively). [68Ga]Ga-FAPI-46 PET did not detect additional lymph nodes beyond those detected with ceCT. Despite detecting fewer lymph nodes overall, [18F]FDG PET identified 6 additional lymph nodes in 5 patients, resulting in clinical nodal upstaging in 4 cases (20%) compared with both [68Ga]Ga-FAPI-46 PET and ceCT. [68Ga]Ga-FAPI-46 PET would have led to clinical metastatic upstaging in 4 patients (20%) because of the identification of potential distant metastases (1 peritoneal and 3 liver metastases), which would have resulted in a change in recommended patient management from curative-intent to palliative treatment in 3 patients (15%). Conclusion: The primary clinical value of [68Ga]Ga-FAPI-46 PET was its ability to detect distant metastases that were negative on [18F]FDG PET and ceCT, potentially impacting patient management. There were no obvious advantages in the evaluation of primary tumor and regional lymph nodes. Although the study population is relatively small and mostly consists of patients with GEJC, this study represents the first prospective investigation of consecutive patients in a well-defined, clinical northern European setting and indicates potential future roles for [68Ga]Ga-FAPI-46 PET in GC and GEJC.
引用
- Bentestuen M, Makieva I, Andersen TB, et al. Clinical Value of [68Ga]Ga-FAPI-46 PET/CT Versus [18F]FDG PET/CT for Primary Staging of Gastroesophageal Adenocarcinoma: Results from a Prospective Northern European Trial. J Nucl Med. 2026. PMID: 42914178. doi:10.2967/jnumed.126.273232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。